We would love to hear your thoughts about our site and services, please take our survey here.
https://twitter.com/blad3sharp/status/1372674363300925440?s=21
https://bidstats.uk/tenders/2020/W24/728563768
This is new, Microgen listed with £120mil. The dates don’t add up though, 2016-2020.
Not a full note, market update:
Market Capitalisation: £490.9m; Share price: 695p; Target Price: 1,433p – BUY
• Diagnostic developer, Novacyt, announced the launch of mobile processing laboratories (MPL) which can perform rapid PCR testing on-site.
• MPLs are to be equipped with PROmateTM, the Group’s direct-to-PCR COVID-19 assay and the Group’s q16 PCR instruments.
• Each MPL is able to process up to 900 COVID-19 samples per day, with results to patients in under 80 minutes.
• Test samples are to be captured using mid-nose nasal swabs, which are more tolerable and less invasive than
nasopharyngeal swabs.
• The PromateTM workflow uses a viral inactivation buffer, which reduces the cost of testing and risks associated with
handling live virus samples.
VersaLabTM, launched by Novacyt in December 2020, aims to support private sector testing for infectious disease. Customers can design a bespoke service to support their testing capabilities. The launch of the MPL service further supports the VersaLabTM offering. MPLs can be deployed at workplaces and schools as well as sporting and music events to provide routine localised mass testing. We expect demand for private sector testing to grow once lockdown restrictions begin to be lifted and companies look to safely return employees back to workplaces. Novacyt is also in the process of validating the use of its SNPsig® portfolio with PROmateTM to enable a mobile testing solution that can discriminate between SARS-CoV-2 variants. This should help healthcare providers to rapidly identify variants which may be driving an outbreak of surge infections in certain areas.
https://twitter.com/blackbirdinvest/status/1371916206727380998?s=21
More Chinese crap.
Twitter on fire tonight, Shaunp not sure if you have all these in your dropbox.
https://twitter.com/blackbirdinvest/status/1371588266156298245?s=21
https://twitter.com/blackbirdinvest/status/1371589433284300802?s=21
https://twitter.com/blackbirdinvest/status/1371585010277433345?s=21
https://twitter.com/blackbirdinvest/status/1371586647859605505?s=21
https://twitter.com/novacytgroup/status/1371513035026751496?s=21
Still upping their game
Geordieshores, the company has hundreds of diagnostic products which aren’t COVID related. Sadly their name wasn’t out and about prior to COVID. They were a tiny company trying to compete with the majors.
Now the Mygo and Mygo mini are globally sold, their tests are known as one of the best in the world they’re getting a name for themselves. This has allowed them to build up a huge network of distributors and customers that allow them to sell non COVID products to.
See below for a recent non COVID tender:
https://twitter.com/gggg2120/status/1370729120125104128?s=21
I see these sales and tenders increasing now the contacts have been made, that’s the majority of the battle.
Garydav, I completely agree. They are in the very early stages of their journey to become a MIDCAP. That journey needs acquisitions and a robust R and D process, both of which cost huge amounts of money.
It would be extremely irresponsible of the management to start paying dividends or doing share buy backs at this stage. Now is the time to invest in the business and other business whilst they’re making huge sums, this will allow growth to continue if COVID revenue reduces.